Clinical Report: Does TYK2/JAK1 Show Potential in Inflammatory Diseases?
Overview
The first-in-human phase 1 trial of SDC-1801, a TYK2/JAK1 inhibitor, demonstrated good tolerability and biomarker changes indicative of pathway inhibition. The study involved 95 healthy participants and highlighted pharmacokinetic properties and safety profiles.
Background
The TYK2/JAK1 signaling pathway is implicated in various inflammatory and autoimmune diseases. Current treatments for conditions like inflammatory bowel disease (IBD) often leave patients unresponsive.
Data Highlights
| Parameter | Value |
|---|---|
| Participants | 95 |
| Dosage Range | 5 mg to 150 mg |
| Peak Plasma Concentration Time | 3 to 5 hours |
| Half-Life | 15 to 27 hours |
| Adverse Events | Mild or moderate |
Key Findings
- SDC-1801 was well tolerated with no serious adverse events reported.
- Headache was the most common treatment-emergent adverse event.
- Pharmacokinetic analyses indicated a half-life of 15 to 27 hours.
- Food intake modestly increased drug exposure, suggesting improved absorption.
- Evidence of pharmacologic activity included reductions in IP-10 and high-sensitivity C-reactive protein.
Clinical Implications
The safety profile and biomarker effects observed in this study were reported, indicating the need for further evaluation of SDC-1801.
Conclusion
The findings from the phase 1 trial of SDC-1801 indicate its safety and pharmacokinetic properties.
Related Resources & Content
- Brearley C, et al., British Journal of Clinical Pharmacology, 2023 -- First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801
- Journal of Crohn's and Colitis — Hit the road JAK: is there still hope left for TYK2 inhibition in IBD?
- Frontiers in Immunology — JAK-STAT pathway-associated skin diseases: a refined functional framework for inflammatory skin diseases
- Journal of Crohn's and Colitis — Discordant Effects of Janus Kinase Inhibition Ex Vivo on Inflammatory Responses in Colonic Compared to Ileal Mucosa
- Frontiers in Immunology — Cardiovascular safety and early myocardial deformation signal after upadacitinib initiation in immune-mediated inflammatory disorders
- Living guideline for pharmacological management of moderate-to-severe ulcerative colitis
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update
- ACG Clinical Guideline Update: Ulcerative Colitis in Adults - PubMed
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update - PMC
- FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions | FDA
- SOTYKTU (deucravacitinib) Highlights of Prescribing Information
- Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials - Armstrong - 2025 - Journal of the European Academy of Dermatology and Venereology - Wiley Online Library
- POS0496 DEUCRAVACITINIB IN MODERATE TO SEVERE PLAQUE PSORIASIS: 5-YEAR, LONG-TERM SAFETY AND EFFICACY RESULTS FROM THE PHASE 3 POETYK PSO-1, PSO-2, AND LTE TRIALS - ScienceDirect
- Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial - PMC
- Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial - PMC
- Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis - PubMed
- Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 AGA Evidence Synthesis - PMC
- Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis - ScienceDirect
- Effectiveness and Safety of Janus Kinase Inhibitors in Acute Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis - Clinical Gastroenterology and Hepatology
- First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801 - Brearley - British Journal of Clinical Pharmacology - Wiley Online Library
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
